Metal-Protein Attenuation with Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial

Archives of Neurology

Volumn 60, Issue 12, 2003, Pages 1685-1691

  Ritchie, Craig W ^a,b,c   Bush, Ashley I ^a,b,h   Mackinnon, Andrew ^b,d   Macfarlane, Steve ^a,b   Mastwyk, Maree ^a,b   MacGregor, Lachlan ^a,e   Kiers, Lyn ^a,e   Cherny, Robert ^a,b   Li, Qiao Xin ^a,b   Tammer, Amanda ^a,b   Carrington, Darryl ^a,b   Mavros, Christine ^a,b   Volitakis, Irene ^a,b   Xilinas, Michel ^f   Ames, David ^b   Davis, Stephen ^a,e   Beyreuther, Konrad ^g   Tanzi, Rudolph E ^h   Masters, Colin L ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CLIOQUINOL; COPPER ION; METAL; PROTEIN; ZINC;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOTOXICITY; CHELATION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DISEASE SEVERITY; DISSOLUTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MALE; METAL BINDING; MICROALBUMINURIA; NAUSEA; NERVE CONDUCTION; NEUROPATHY; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; REFLEX; SCORING SYSTEM; SIDE EFFECT; TACHYCARDIA; VISUAL IMPAIRMENT; ZINC BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CHELATING AGENTS; CLIOQUINOL; COGNITION; COPPER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; ZINC;

EID: 10744224267     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.12.1685     Document Type: Article

References (17)

1. Simons M, Schwärzler F, Lütjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomised, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346-350.
2. Hock C, Konietzko U, Streffer JR, et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547-554.
3. Opazo C, Huang X, Cherny R, et al. Metalloenzyme-like activity of Alzheimer's disease β-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H2O2. J Biol Chem. 2002;277:40302-40308.
4. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J Biol Chem. 1999;274:23223-23228.
5. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30:665-676.
6. Barnham KJ, Ciccotosto GD, Tickler AK, et al. Neurotoxic, redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem. In press.
7. Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary/mechanism of amyloid neurotoxicity. J Neurosci. 2003;23:5088-5095.
8. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. Changes in uptake of vitamin B12 and trace metals in brains of mice treated with clioquinol. J Neurol Sci. 2000;173:40-44.
9. Regland B, Lehmann W, Abedini I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord. 2001;12:408-414.
10. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
11. McLean C, Cherny R, Fraser F, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860-866.
12. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46:412-416.
13. Buxbaum JD, Cullen EI, Freidhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer β-amyloid peptide in vitro and in patients. Front Biosci. 2002;7:a50-a59.
14. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse/model of Alzheimer's disease. Science. 2002;295:2264-2267.
15. Jensen M, Schroder J, Blomberg M, et al. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol. 1999;45:504-511.
16. Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol. 1989;34:31-43.
17. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 2003;37:899-909.